Jeffrey A. Engelman
Massachusetts General Hospital
2 papers in the Anchorcite directory, published between 2007 and 2010, cited 9,039 times in total.
ORCID profileResearch topics
- Lung Cancer Treatments and Mutations · 2 papers
- HER2/EGFR in Cancer Research · 1 paper
- Cancer Genomics and Diagnostics · 1 paper
- Lung Cancer Diagnosis and Treatment · 1 paper
- Lung Cancer Research Studies · 1 paper
Frequent co-authors
- James G. Christensen · 2 papers
- Pasi Antero Janne · 2 papers
- Kreshnik Zejnullahu · 1 paper
- Tetsuya Mitsudomi · 1 paper
- Youngchul Song · 1 paper
- Courtney Hyland · 1 paper
- Joon Oh Park · 1 paper
- Neal Ian Lindeman · 1 paper
Papers
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience · 2007 · 4,559 citations
The epidermal growth factor receptor (EGFR) kinase inhibitors gefitinib and erlotinib are effective treatments for lung cancers with EGFR activating mutations, but these tumors invariably develop drug resistance. Here, we describe a gefitinib-sensitive lung cancer cell line that developed resistance…
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerNew England Journal of Medicine · 2010 · 4,480 citations
BACKGROUND: Oncogenic fusion genes consisting of EML4 and anaplastic lymphoma kinase (ALK) are present in a subgroup of non-small-cell lung cancers, representing 2 to 7% of such tumors. We explored the therapeutic efficacy of inhibiting ALK in such tumors in…
Metadata from OpenAlex (CC0).